A00016 - Joko Widodo, Indonesian Politician

Widodo, Joko
Joko Widodo (b. June 21, 1961) is an Indonesian politician who became the governor of Jakarta. He was often better known by his nickname Jokowi. He was previously the mayor of Surakarta (often also known as Solo in Indonesia). He was nominated by his party, the Indonesian Democratic Party - Struggle (PDI-P), to run in the 2012 Jakarta gubernatorial election with Basuki Tjahaja Purnama (often known as Ahok) as his running mate. He was elected governor of Jakarta on September 20, 2012 after a second round runoff election in which he defeated the incumbent governor Fauzi Bowo.  Jokowi's win was widely seen as reflecting popular voter support for "new" or "clean" leaders rather than the "old" style of politics in Indonesia, even though Jokowi was over 50 years old at the time.  

Jokowi's popularity rose sharply after his election to the high-profile position of governor of Jakarta in 2012. During 2013 and early 2014, he was seen as a potential PDI-P candidate for the Indonesian presidential election in 2014. 

A00015 - Casey Kasem, Wholesome Voice of Pop Radio

Kasem, Casey

Casey Kasem (b. April 27, 1932, Detroit, Mich.— d. June 15, 2014, Gig Harbor, Wash.), was born Kemal Amin Kasem. Kasem was born in Detroit, Michigan, on April 27, 1932, to Lebanese Druze immigrant parents. They settled in Michigan, where they worked as grocers.

Kasem became an American disc jockey who filled the airways for 34 years (1970–2004) with his weekly nationally syndicated Top 40 radio shows, including American Top 40, which he created and hosted with a hallmark easygoing style. During the program’s four-hour format, Kasem provided listeners not only with an upbeat analysis of the songs that had made the list (gleaned from Billboard magazine’s most popular singles of the previous week) but also with personal tidbits about the artists behind the music. Kasem’s courtly voice and popular catchphrases, including his signature sign-off, “Keep your feet on the ground and keep reaching for the stars,” made him one of the country’s most recognizable radio personalities. Kasem also fronted American Top 20 and American Top 10.  He retired as host from those radio shows in 2009. In addition to his radio work, Kasem appeared in a few films, including The Incredible Two-Headed Transplant(1971) and Ghostbusters (1984, as himself), and provided the voice of Shaggy on the cartoon series Scooby-Doo and for Robin “the Boy Wonder” on the animated The Batman/Superman Hour (1968–69). He was inducted into the Radio Hall of Fame in 1992.

A00014 - Fouad Ajami, Commentator and Expert in Arab History

Fouad A. Ajami (Arabic: فؤاد عجمي‎; September 18, 1945 – June 22, 2014), was a MacArthur Fellowship winning, Lebanese-born American university professor and writer on Middle Eastern issues. He was a senior fellow at Stanford University's Hoover Institution.

Ajami was an outspoken supporter of the Iraq War, the nobility of which he believed there "can be no doubt".

A00013 - Ahmed Abu Khattala, Islamist Militia Commander in Libya

Khattala, Ahmed Abu

Ahmed Abu Khattala (born c. 1971) was a Islamist militia commander in Libya, a commander of Ansar al-Sharia militia. He is suspected of participating in the 2012 Benghazi attack on the American diplomatic mission at Benghazi, in which the American Ambassador and three other Americans were killed. In a December 2013 investigation of the attack, the New York Times described Abu Khattala as a central figure.  However, Abu Khattala denied killing the Americans or being part of the attack.

Abu Khattala spent most of his adult life in Abu Salim prison in Tripoli, jailed by the Qaddafi government for his Islamist views. During the 2011 uprising against Qaddafi in Libya, he formed his own militia of perhaps two dozen fighters, naming it Obeida Ibn Al Jarra for an early Islamic general. He later became involved in Ansar al-Shariah, a group of as many as 200 militants who, had broken away from the other militias in 2012 in protest of those militia's support for parliamentary elections in Libya.  Abu Khattala opposed American involvement in Libya and in interviews with the New York Times stated that “the enmity between the American government and the peoples of the world is an old case.” In regards to the role of the air campaign of NATO that overthrew Colonel Qaddafi, he believed that if NATO had not intervened, “God would have helped us.” He also claimed that, “We know the United States was working with both sides” and considering “splitting up" Libya.

Witnesses of the September 11, 2012 attack on the American diplomatic compound in Benghazi say they saw Abu Khattala leading the attack. On August 6, 2013, United States officials confirmed that Abu Khattala had been charged with playing a significant role in the attack. 

On the weekend of June 14 to June 15, 2014, U.S. Special Forces captured Abu Khattala in a covert mission in Libya. Khattala is one of the suspected leaders of the 2012 Benghazi attack. 

A00012 - Malik Bendjelloul, Oscar Winner for "Searching for Sugar Man"

Bendjelloul, Malik

Malik Bendjelloul (September 14, 1977 – May 13, 2014) was an Algerian Swedish Academy-Award-winning  documentary filmmaker, journalist and former child actor. He is best known for his 2012 documentary, Searching for Sugar Man, which won an Academy Award and a BAFTA Award.

A00011 - Nazim al-Haqqani, Sufi Spiritual Leader

Nazim al-Haqqani or Mehmet Nâzım Adil (Arabic: محمد ناظم الحقاني ‎, April 21, 1922  / Sha'ban  23, 1340 AH – May 7, 2014), formally referred to as Muhammad Nazim Adil al-Qubrusi al-Haqqani (Turkish: Nazım Kıbrısi), often called Shaykh (or Sheikh) Nazim, was a Turkish Cypriot Sufi Sheikh and leader of the Naqshbandi-Haqqani Order.

A00010 - Hunein Maassab, Developer of Nasal Spray Flu Vaccine

Hunein Maassab (b.  June 11, 1926, Damascus,  - d.  February 1, 2014, North Carolina) was the developer of nasal spray flu vaccine.  He was born on June 11, 1926, in Damascus. His father was a jeweler. He enrolled at the University of Missouri, where he received a bachelor’s degree in biology in 1950 and a master’s in physiology and pharmacology in 1952. He then moved to Michigan, where he earned a master’s degree in public health in 1954 and his doctorate in epidemiology in 1956.

"John" Hunein F. Maassab was a Professor in the Department of Epidemiology at the University of Michigan since 1960 and served as the chairman from 1991-1997. He founded and directed the Hospital and Molecular Epidemiology program in the Department of Epidemiology. Dr. Maassab was a member of several scientific organizations including the American Public Health Association and the American Society of Microbiology and was a Fellow of the American Academy of Microbiology. Dr. Maassab had over 170 publications that range from studies on the basic biology of viruses to research on the development of methods to control viral infections.

Dr. Maassab was awarded patents for the development of a cold-adapted influenza virus and for an attenuated respiratory syncytial virus. Dr. Maassab received the 1997 Award for Science and Technology from Popular Science for the development of the cold-adapted influenza virus. This discovery led him to develop a flu vaccine that can be administered by a nasal spray as an alternative to the "flu shot."

Influenza, commonly called "the flu," is an infection of the respiratory tract caused by the influenza virus. Compared with most other viral respiratory infections, such as the common cold, influenza infection often causes a more severe illness. Most people who get the flu recover completely in one to two weeks, but some people develop serious and potentially life-threatening medical complications, such as pneumonia. Between 25-50 million people in the United States are infected each year with the influenza virus. In an average year, infection with influenza virus is associated with 20,000 deaths nationwide and more than 100,000 hospitalizations. Approximately 90 million workdays are lost and 30 million school days are missed each year as a result of influenza.

Vaccination can prevent disease caused by influenza. Unlike vaccines used against other viruses such as measles, mumps, rubella and varicella, people need to be vaccinated annually against influenza. This is because the influenza virus often changes its genetic composition to evade the immune system of its host. Thus, people are susceptible to influenza virus infection throughout life. The current vaccine used for flu is a "killed" virus vaccine that is administered by injection. The Centers for Disease Control and Prevention recommends a flu shot for healthy adults over age 50 and high-risk children and adults. Unfortunately, less than one percent of healthy children and less than 30 percent of healthy adults, are routinely vaccinated. Achieving adequate flu protection is difficult because each year a new vaccine must be developed that is appropriate for the specific strainsof influenza likely to circulate. Currently, there is concern n the public health community regarding the timely supply of vaccine for the coming flu season.

In 1967, Dr. Maassab published a paper in the journal Nature describing the adaptation of an influenza virus for growth at a low temperature in culture. Importantly, this "cold-adapted" virus does not grow at higher temperatures such as those found in the lungs. However, the cold-adapted virus can replicate in the nasal passages where the temperature is lower. The cold-adapted virus cannot survive in the lungs where the body temperature is higher, and therefore cannot cause disease. The limited viral growth seen in the nasal passages may stimulate an immune response that may protect a person from infections from influenza viruses. This protection also prevents the spread of influenza to others.

Dr. Maassab developed an intranasal cold-adapted live virus vaccine that may provide promising alternative to the "flu shot." Using a nasal mist, an attenuated (weakened) live form of the influenza virus is sprayed into the nasal passages, where influenza viruses enter the body.

The public health significance of this finding for the development of an influenza vaccine was apparent. By using nasal mist technology to eliminate the fear of injections, this method may offer the first practical way to immunize children and adults on a large scale annually in the near future.